Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Candy S. Peskey"'
Autor:
Michelle A. Elliott, Candy S. Peskey, Naseema Gangat, Mrinal M. Patnaik, Kristen B. McCullough, Aref Al-Kali, William J. Hogan, Ross A. Dierkhising, Kristin C. Mara, Jason N. Barreto, Mark R. Litzow, Dennis A. Gastineau, Louis Letendre
The optimal antithrombin(AT) activity parameters for replacement as thromboprophylaxis following asparaginase remains unclear. This single-center, retrospective study evaluated two sets of AT replacement thresholds and targets in adults receiving asp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c122889bd62213ab1603b22ed14ee7db
https://europepmc.org/articles/PMC5546319/
https://europepmc.org/articles/PMC5546319/
Autor:
Kristen B. McCullough, William J. Hogan, Michelle A. Elliott, Candy S. Peskey, Louis Letendre, Dennis A. Gastineau, Aref Al-Kali, Mrinal M. Patnaik, Jason N. Barreto, Mark R. Litzow
Publikováno v:
Blood. 122:3873-3873
Background L-asparaginase (LASP) therapy in adults is associated with frequent hepatic and metabolic side effects, often resulting in dose adjustments and omissions. Pegylated asparaginase (PEGASP) substituted for LASP improves convenience of adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e7b6e526a1b38c9b1130964885fbee6
https://doi.org/10.1182/blood.v122.21.3873.3873
https://doi.org/10.1182/blood.v122.21.3873.3873
Autor:
Candy S. Peskey, Mark R. Litzow, Jason N. Barreto, Naseema Gangat, William J. Hogan, Mrinal M. Patnaik, Dennis A. Gastineau, Michelle A. Elliott, Kristen B. McCullough
Publikováno v:
Blood. 122:1732-1732
Introduction L-asparaginase therapy results in systemic depletion of antithrombin (AT) and fibrinogen (FG), resulting in thrombotic (TE) and hemorrhagic events (HE). Prophylactic correction of coagulation disturbances have been inconclusive with rega
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ee8af534a56ec32b8194095d71e95dc
https://doi.org/10.1182/blood.v122.21.1732.1732
https://doi.org/10.1182/blood.v122.21.1732.1732
Autor:
Jason N. Barreto, Kristen B. McCullough, Candy S Peskey, Louis Letendre, William Hogan, Aref Al-Kali, Mark R. Litzow, Mrinal M. Patnaik
Publikováno v:
Blood. 122:1405-1405
Background L-asparaginase (LASP) therapy in adults is associated with frequent hepatic and metabolic side effects, often resulting in dose adjustments and omissions. Pegylated asparaginase (PEGASP) substituted for LASP improves convenience of adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1065d54b8d98cd65574d3957a0328e7d
https://doi.org/10.1182/blood.v122.21.1405.1405
https://doi.org/10.1182/blood.v122.21.1405.1405